Abstract 1571P
Background
In France, oncology is one of the disciplines for which the percentage of residents reorientating at the start of internship towards another specialty is the highest (8-10%). The determinants of this reorientation are unknown.
Methods
We conducted a quantitative online survey with the 121 interns of the 2022-2023 class during their 1st year of oncology training, with 2 follow-ups over 2 months. 36 potential determinants from previous works (Wright et al. 2004; Beaulieu et al. 2010) were evaluated using a 5-point Likert scale alongside parameters describing the resident. We also assessed their satisfaction with the teaching received. We conducted univariate and multivariate linear regression analyses.
Results
The response rate was 107/121 (88.5%), but 99 questionnaires were usable for the determinants analysis (81.2%). 9 residents were considering or may consider changing speciality. In multivariate analysis, 3 factors were associated with considering a change of specialty: “desire for social commitment” (β=2.15, p=.025), “other experience during the 2 nd -cycle hospital traineeships” (β=3.64, p<.001) and “interest in emergency care” (β=2.13, p=.028). Satisfaction with the education received was negatively associated with the desire to change specialty (β=-3.49, p<.001). The determinants of satisfaction in oncology training were: “being able to move to the desired university” (β=4.24, p=.016), “an image of dynamism of oncology” (β=4.68, p<.001); on the other hand, the “desire for short training” was negatively associated with satisfaction with oncology training (β=0.281, p=.042).
Conclusions
We identified 2 intrinsic factors (social commitment and interest in emergency care) and 2 extrinsic factors (other significant experiences during 2nd-cycles hospital traineeships and low satisfaction in oncology training) as being able to explain the wish of reorientation among oncology residents.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Centre Oscar Lambret.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1594P - Cancer mortality in young population and estimated radon areas in Spain
Presenter: Miquel Ferriol-Galmés
Session: Poster session 10
1598P - Xaluritamig, a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Initial results from dose expansion cohorts in a phase I study
Presenter: William Kelly
Session: Poster session 10
1600P - Phase II trial of pembrolizumab and lenvatinib in advanced neuroendocrine prostate cancer (NEPC)
Presenter: Ulka Vaishampayan
Session: Poster session 10
1601P - First results from ZZFIRST: A randomized phase II trial of enzalutamide (EZ) with or without talazoparib (TALA) in metastatic hormone-naïve prostate cancer (mHNPC)
Presenter: Joaquin Mateo
Session: Poster session 10
1602P - CBP-1018, Bi-ligand-drug conjugate (Bi-XDC) drug treated for metastatic castration resistant prostate cancer (mCRPC) patients from phase I study results
Presenter: Kaiwen Li
Session: Poster session 10
1603P - Updated safety and efficacy of tazemetostat (TAZ) plus enzalutamide (ENZ) in patients with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Wassim Abida
Session: Poster session 10
1604P - PSMA-targeted radioligand therapy (RLT) with 131I-LNTH-1095 (1095) plus enzalutamide (enza) vs enza alone in chemotherapy-naïve patients (pts) whose piflufolastat F 18-avid metastatic castration-resistant prostate cancer (mCRPC) progressed on abiraterone (abi): ARROW
Presenter: Evan Yu
Session: Poster session 10
1605P - Opevesostat (MK-5684/ODM-208), an oral CYP11A1 inhibitor, in metastatic castration-resistant prostate cancer (mCRPC): Updated CYPIDES phase II results
Presenter: Karim Fizazi
Session: Poster session 10
1606P - Mature follow up of phase I dose finding trial of pembrolizumab (pembro) with AR inhibitors (ARI) and priming tumour-targeted radiation with anti-PSMA alpha emitter 225Ac-J591
Presenter: Aaron Holmes
Session: Poster session 10